Birchview Capital, LP’s Celldex Therapeutics Inc New Position
Does Birchview Capital, LP own Celldex Therapeutics Inc New (TCE2)? Yes — 70.1K shares worth $2M (+1.27% of its 13F portfolio) as of Q1 2026.
Position Value
$2M
Q1 2026
Shares
70.1K
% of Portfolio
+1.27%
Quarters Held
1
currently held
Position History TCE2
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 70.1K | $2M | +1.27% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Birchview Capital, LP’s full portfolio or all institutional holders of TCE2.